Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
2.170
-0.060 (-2.69%)
At close: Feb 27, 2026, 4:00 PM EST
2.150
-0.020 (-0.92%)
After-hours: Feb 27, 2026, 7:46 PM EST
Processa Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 5.61 | 4.78 | 5.66 | 8.76 | 4.69 | 3.26 | |
| Research & Development | 7.41 | 7.27 | 5.8 | 11.49 | 6.88 | 3.17 | |
| Operating Expenses | 13.02 | 12.05 | 11.46 | 20.26 | 11.57 | 6.44 | |
| Operating Income | -13.02 | -12.05 | -11.46 | -20.26 | -11.57 | -6.44 | |
| Interest Expense | - | - | - | - | - | -0.28 | |
| Interest & Investment Income | 0.08 | 0.2 | 0.34 | 0.1 | 0.01 | 0 | |
| EBT Excluding Unusual Items | -12.93 | -11.85 | -11.12 | -20.16 | -11.56 | -6.71 | |
| Asset Writedown | - | - | - | -7.27 | - | - | |
| Other Unusual Items | - | - | - | - | 0.16 | - | |
| Pretax Income | -12.93 | -11.85 | -11.12 | -27.42 | -11.96 | -15.41 | |
| Income Tax Expense | - | - | - | - | -0.53 | -1 | |
| Net Income | -12.93 | -11.85 | -11.12 | -27.42 | -11.43 | -14.41 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 4.63 | |
| Net Income to Common | -12.93 | -11.85 | -11.12 | -27.42 | -11.43 | -19.04 | |
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 669.62% | 133.30% | 62.83% | 5.16% | 104.27% | 35.71% | |
| EPS (Basic) | -16.58 | -96.82 | -211.99 | -851.18 | -372.97 | -1269.40 | |
| EPS (Diluted) | -16.58 | -96.82 | -211.99 | -851.18 | -372.97 | -1269.40 | |
| Free Cash Flow | -10.73 | -11.25 | -8.07 | -9.61 | -8.72 | -3.14 | |
| Free Cash Flow Per Share | -13.76 | -91.90 | -153.75 | -298.12 | -284.52 | -209.56 | |
| EBITDA | -13.02 | -12.05 | -11.46 | -19.47 | -10.78 | -5.63 | |
| D&A For EBITDA | 0 | 0 | 0 | 0.79 | 0.79 | 0.8 | |
| EBIT | -13.02 | -12.05 | -11.46 | -20.26 | -11.57 | -6.44 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.